European Medicines Agency : First cell-based gene therapy to treat adult patients with multiple myeloma
On 25 June 2021, EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Abecma (idecabtagene vicleucel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three previous therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment.
For more information, please have a look at the EMA press release.
OpenEdition vous propose de citer ce billet de la manière suivante :
egennet (25 juin 2021). European Medicines Agency : First cell-based gene therapy to treat adult patients with multiple myeloma. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/o5rv





